Atherosclerotic cardiovascular disease events among adults with high predicted risk without established risk factors

被引:3
作者
Kong, Nathan [1 ]
Sakhuja, Swati [2 ]
Colantonio, Lisandro D. [2 ]
Levitan, Emily B. [2 ]
Lloyd-Jones, Donald M. [3 ]
Cushman, Mary [4 ]
Muntner, Paul [5 ]
Polonsky, Tamar S. [1 ]
机构
[1] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[2] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA
[3] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL USA
[4] Univ Vermont, Dept Med, Larner Coll Med, Burlington, VT USA
[5] Ctr Dis Control & Prevent, Off Sci, Atlanta, GA USA
来源
AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2024年 / 17卷
基金
美国国家卫生研究院;
关键词
Cohort study; Preventative cardiology; ASCVD risk; CORONARY-HEART-DISEASE; ALL-CAUSE; PHYSICAL-ACTIVITY; AMERICAN-COLLEGE; ASSESSMENT TOOL; DIET QUALITY; OLDER-ADULTS; ASSOCIATION; AGE; POLYPHARMACY;
D O I
10.1016/j.ajpc.2023.100612
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Age is the strongest contributor to 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk. Some older adults have a predicted ASCVD risk >= 7.5 %, without established risk factors. We sought to compare ASCVD incidence among adults with predicted ASCVD risk >= 7.5 %, with and without established ASCVD risk factors, to adults with predicted risk <7.5 %.Methods: We analyzed data from REasons for Geographic and Racial Differences in Stroke study participants, 45-79 years old, without ASCVD or diabetes, not taking statins and with low-density lipoprotein cholesterol 70-189 mg/dL. Participants were categorized into 3 groups based on their 10-year predicted ASCVD risk and presence of established risk factors: <7.5 %, >= 7.5 % with established risk factors and >= 7.5 % without established risk factors. Established risk factors included smoking, systolic blood pressure >= 130 mmHg or antihypertensive medication use, total cholesterol >= 200 mg/dL, or high-density lipoprotein cholesterol <50 mg/dL for women (<40 mg/dL for men). Participants were followed for ASCVD events.Results: Among 11,115 participants, 911 incident ASCVD events occurred over a median of 11.1 years. ASCVD incidence rates were 3.6, 12.8, and 9.8 per 1,000 person-years for participants with predicted risk <7.5 %, predicted risk >= 7.5 % with established risk factors and predicted risk >= 7.5 % without established risk factors, respectively. Compared to adults with predicted risk <7.5 %, hazard ratios for incident ASCVD in participants with risk >= 7.5 % with and without established risk factors were 3.58 (95 %CI 3.03 - 4.21) and 2.72 (95 %CI 1.91-3.88), respectively.Conclusions: Adults with a 10-year predicted ASCVD risk >= 7.5 % but without established risk factors had a high ASCVD incidence.
引用
收藏
页数:9
相关论文
共 39 条
  • [11] Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
    Fulcher, Jordan
    Mihaylova, Borislaya
    O'Connell, Rachel
    Emberson, Jonathan
    Blackwell, Lisa
    Reith, Christina
    Koren, Michael
    Tonkin, Andrew
    Ridker, Paul
    Barnes, Elizabeth
    Ford, Ian
    Packard, Chris
    Lonn, Eva
    Wanner, Christoph
    Koenig, Wolfgang
    Gotto, Antonio
    Kjekshus, John
    Yusuf, Salim
    Collins, Rory
    Simes, John
    Baigent, Colin
    Keech, Anthony
    de Lemos, J.
    Braunwald, E.
    Blazing, M.
    Murphy, S.
    Downs, J. R.
    Gotto, A.
    Clearfield, M.
    Holdaas, H.
    Gordon, D.
    Davis, B.
    Koren, M.
    Dahlof, B.
    Poulter, N.
    Sever, P.
    Knopp, R. H.
    Fellstrom, B.
    Jardine, A.
    Schmieder, R.
    Zannad, F.
    Colhoun, H. M.
    Betteridge, D. J.
    Durrington, P. N.
    Hitman, G. A.
    Fuller, J.
    Neil, A.
    Sacks, F.
    Moye, L.
    Pfeffer, M.
    [J]. LANCET, 2019, 393 (10170) : 407 - 415
  • [12] Goff DC, 2014, Circulation, V129, pS49, DOI [DOI 10.1161/01.CIR.0000437741.48606.98, 10.1161/01.cir.0000437741.48606.98]
  • [13] Statin Adverse Effects A Review of the Literature and Evidence for a Mitochondrial Mechanism
    Golomb, Beatrice A.
    Evans, Marcella A.
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2008, 8 (06) : 373 - 418
  • [14] Assembling and validating a heart failure-free cohort from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study
    Goyal, Parag
    Mefford, Matthew T.
    Chen, Ligong
    Sterling, Madeline R.
    Durant, Raegan W.
    Safford, Monika M.
    Levitan, Emily B.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2020, 20 (01)
  • [15] Grundy SM, 2019, J AM COLL CARDIOL, V73, P3168, DOI [10.1161/CIR.0000000000000625, 10.1016/j.jacc.2018.11.002, 10.1016/j.jacc.2018.11.003]
  • [16] Polypharmacy Management in Older Patients
    Hoel, Robert William
    Connolly, Ryan M. Giddings
    Takahashi, Paul Y.
    [J]. MAYO CLINIC PROCEEDINGS, 2021, 96 (01) : 242 - 256
  • [17] Disparities in Stroke Incidence Contributing to Disparities in Stroke Mortality
    Howard, Virginia J.
    Kleindorfer, Dawn O.
    Judd, Suzanne E.
    McClure, Leslie A.
    Safford, Monika M.
    Rhodes, J. David
    Cushman, Mary
    Moy, Claudia S.
    Soliman, Elsayed Z.
    Kissela, Brett M.
    Howard, George
    [J]. ANNALS OF NEUROLOGY, 2011, 69 (04) : 619 - 627
  • [18] The reasons for geographic and racial differences in stroke study: Objectives and design
    Howard, VJ
    Cushman, M
    Pulley, L
    Gomez, CR
    Go, RC
    Prineas, RJ
    Graham, A
    Moy, CS
    Howard, G
    [J]. NEUROEPIDEMIOLOGY, 2005, 25 (03) : 135 - 143
  • [19] 'Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?' No, but we can improve risk communication metrics
    Jackson, Rod
    Kerr, Andrew
    Wells, Sue
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 (20) : 1548 - 1552
  • [20] Is Age Really a Non-Modifiable Cardiovascular Risk Factor?
    Kannel, William B.
    Vasan, Ramachandran S.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (09) : 1307 - 1310